{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:01:04Z","timestamp":1760234464885,"version":"build-2065373602"},"reference-count":94,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>More than one year into the novel coronavirus disease 2019 (COVID-19) pandemic, healthcare systems across the world continue to be overwhelmed with soaring daily cases. The treatment spectrum primarily includes ventilation support augmented with repurposed drugs and\/or convalescent plasma transfusion (CPT) from recovered COVID-19 patients. Despite vaccine variants being recently developed and administered in several countries, challenges in global supply chain logistics limit their timely availability to the wider world population, particularly in developing countries. Given the measured success of conventional CPT in treating several infections over the past decade, recent studies have reported its effectiveness in decreasing the duration and severity of COVID-19 symptoms. In this review, we conduct a literature search of published studies investigating the use of CPT to treat COVID-19 patients from January 2020 to January 2021. The literature search identified 181 records of which 39 were included in this review. A random-effects model was used to aggregate data across studies, and mortality rates of 17 vs. 32% were estimated for the CPT and control patient groups, respectively, with an odds ratio (OR) of 0.49. The findings indicate that CPT shows potential in reducing the severity and duration of COVID-19 symptoms. However, early intervention (preferably within 3 days), recruitment of donors, and plasma potency introduce major challenges for its scaled-up implementation. Given the low number of existing randomized clinical trials (RCTs, four with a total of 319 patients), unanticipated risks to CPT recipients are highlighted and discussed. Nevertheless, CPT remains a promising COVID-19 therapeutic option that merits internationally coordinated RCTs to achieve a scientific risk\u2013benefit consensus.<\/jats:p>","DOI":"10.3390\/v13050849","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T22:36:24Z","timestamp":1620426984000},"page":"849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Convalescent Plasma Transfusion for the Treatment of COVID-19 in Adults: A Global Perspective"],"prefix":"10.3390","volume":"13","author":[{"given":"Saly","family":"Kanj","sequence":"first","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7804-8050","authenticated-orcid":false,"given":"Basem","family":"Al-Omari","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi 127788, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"unstructured":"WHO (2021, January 26). Coronavirus (COVID-19). Available online: https:\/\/who.sprinklr.com\/.","key":"ref_4"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: Living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"doi-asserted-by":"crossref","unstructured":"Van Oosterhout, C., Hall, N., Ly, H., and Tyler, K.M. (2021). COVID-19 Evolution during the Pandemic\u2013Implications of New SARS-CoV-2 Variants on Disease Control and Public Health Policies, Taylor & Francis.","key":"ref_6","DOI":"10.1080\/21505594.2021.1877066"},{"unstructured":"WHO (2020). Clinical Management of Severe Acute Respiratory Infections (SARI) When COVID-19 Disease Is Suspected, WHO. Interim Guidance.","key":"ref_7"},{"unstructured":"FDA (2020). Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment, Food and Drug Administration.","key":"ref_8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"doi-asserted-by":"crossref","unstructured":"Cunningham, A.C., Goh, H.P., and Koh, D. (2020). Treatment of COVID-19: Old Tricks for New Challenges, Springer.","key":"ref_11","DOI":"10.1186\/s13054-020-2818-6"},{"unstructured":"Corum, J., Grady, D., Wee, S.-L., and Zimmer, C. (2020). Coronavirus Vaccine Tracker, The New York Times.","key":"ref_12"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","article-title":"Looking beyond COVID-19 vaccine phase 3 trials","volume":"27","author":"Kim","year":"2021","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1016\/S2214-109X(20)30136-4","article-title":"COVID-19 and risks to the supply and quality of tests, drugs, and vaccines","volume":"8","author":"Newton","year":"2020","journal-title":"Lancet Glob. Health"},{"doi-asserted-by":"crossref","unstructured":"Koyama, T., Weeraratne, D., Snowdon, J.L., and Parida, L. (2020). Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens, 9.","key":"ref_15","DOI":"10.20944\/preprints202004.0024.v1"},{"doi-asserted-by":"crossref","unstructured":"Yao, H.-P., Lu, X., Chen, Q., Xu, K., Chen, Y., Cheng, L., Liu, F., Wu, Z., Wu, H., and Jin, C. (2021, May 06). Patient-Derived Mutations Impact Pathogenicity of SARS-CoV-2. CELL-D-20-01124. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.04.14.20060160v2.","key":"ref_16","DOI":"10.1101\/2020.04.14.20060160"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrg.2016.104","article-title":"Genetic drift, selection and the evolution of the mutation rate","volume":"17","author":"Lynch","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_20","first-page":"152","article-title":"Convalescent plasma: New evidence for an old therapeutic tool?","volume":"14","author":"Marano","year":"2016","journal-title":"Blood Transfus."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/14787210.2017.1328278","article-title":"Use of human immunoglobulins as an anti-infective treatment: The experience so far and their possible re-emerging role","volume":"15","author":"Bozzo","year":"2017","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis","volume":"211","author":"Baillie","year":"2015","journal-title":"J. Infect. Dis."},{"unstructured":"FDA (2020). Recommendations for Investigational COVID-19 Convalescent Plasma, Content Current as of: 04\/13\/2020, Food and Drug Administration.","key":"ref_23"},{"doi-asserted-by":"crossref","unstructured":"Joyner, M.J., Klassen, S.A., Senefeld, J., Johnson, P.W., Carter, R.E., Wiggins, C.C., Shoham, S., Grossman, B.J., Henderson, J.P., and Musser, J.M. (2020). Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. medRxiv.","key":"ref_24","DOI":"10.1101\/2020.07.29.20162917"},{"doi-asserted-by":"crossref","unstructured":"Valk, S.J., Piechotta, V., Chai, K.L., Doree, C., Monsef, I., Wood, E.M., Lamikanra, A., Kimber, C., McQuilten, Z., and So-Osman, C. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A rapid review. Cochrane Database Syst. Rev.","key":"ref_25","DOI":"10.1002\/14651858.CD013600"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jama.2020.10044","article-title":"Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial","volume":"324","author":"Li","year":"2020","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e20200702","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China","volume":"145","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jpeds.2020.05.007","article-title":"Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region","volume":"223","author":"DeBiasi","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/INF.0000000000002660","article-title":"Coronavirus infections in children including COVID-19: An overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children","volume":"39","author":"Zimmermann","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/apa.15270","article-title":"Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults","volume":"109","author":"Ludvigsson","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E536","DOI":"10.1503\/cmaj.200648","article-title":"Treatment of patients with nonsevere and severe coronavirus disease 2019: An evidence-based guideline","volume":"192","author":"Ye","year":"2020","journal-title":"CMAJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2020002507","article-title":"COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease","volume":"4","author":"Rodriguez","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102956","DOI":"10.1016\/j.transci.2020.102956","article-title":"Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia","volume":"60","author":"Shankar","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102866","DOI":"10.1016\/j.transci.2020.102866","article-title":"First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia","volume":"59","author":"Figlerowicz","year":"2020","journal-title":"Transfus. Apher. Sci."},{"doi-asserted-by":"crossref","unstructured":"Ma\u0142ecki, P., Faltin, K., Mania, A., Mazur-Melewska, K., Cwali\u0144ska, A., Zawadzka, A., Bukowska, A., Lisowska, K., Graniczna, K., and Figlerowicz, M. (2021). Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series. Life, 11.","key":"ref_35","DOI":"10.3390\/life11030247"},{"unstructured":"Gempeler, A., Rada, G., and Rojas, L. (2021, May 06). Convalescent Plasma for the Treatment of Patients with COVID-19: A Living Systematic Review. PROSPERO 2020 CRD42020180703. Available online: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020180703.","key":"ref_36"},{"doi-asserted-by":"crossref","unstructured":"Chai, K.L., Valk, S.J., Piechotta, V., Kimber, C., Monsef, I., Doree, C., Wood, E.M., Lamikanra, A.A., Roberts, D.J., and McQuilten, Z. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: A living systematic review. Cochrane Database Syst. Rev.","key":"ref_37","DOI":"10.1002\/14651858.CD013600.pub3"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jmv.25961","article-title":"Convalescent plasma transfusion for the treatment of COVID-19: Systematic review","volume":"92","author":"Rajendran","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107262","DOI":"10.1016\/j.intimp.2020.107262","article-title":"Convalescent plasma may be a possible treatment for COVID-19: A systematic review","volume":"91","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12026-020-09169-x","article-title":"A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy","volume":"69","author":"Devarasetti","year":"2021","journal-title":"Immunol. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/vox.12973","article-title":"Clinical use of convalescent plasma in the covid-19 pandemic: A transfusion-focussed gap analysis with recommendations for future research priorities","volume":"116","author":"Bloch","year":"2021","journal-title":"Vox Sang."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"unstructured":"(2020). MATLAB Version 9.8.0 (R2020a), The MathWorks Inc.","key":"ref_44"},{"unstructured":"Martinez, W.L., Martinez, A.R., and Solka, J. (2017). Exploratory Data Analysis with MATLAB, CRC Press.","key":"ref_45"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S1053-8119(09)70882-1","article-title":"A Matlab toolbox for the statistical analysis of univariate and multivariate surface and volumetric data using linear mixed effects models and random field theory","volume":"47","author":"Worsley","year":"2009","journal-title":"NeuroImage"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2307\/3002019","article-title":"An approximate distribution of estimates of variance components","volume":"2","author":"Satterthwaite","year":"1946","journal-title":"Biom. Bull."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"m3939","DOI":"10.1136\/bmj.m3939","article-title":"Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial)","volume":"371","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"doi-asserted-by":"crossref","unstructured":"Avendano-Sola, C., Ramos-Martinez, A., Munez-Rubio, E., Ruiz-Antoran, B., de Molina, R.M., Torres, F., Fernandez-Cruz, A., Callejas-Diaz, A., Calderon, J., and Payares-Herrera, C. (2020). Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv.","key":"ref_49","DOI":"10.1101\/2020.08.26.20182444"},{"doi-asserted-by":"crossref","unstructured":"Rasheed, A.M., Fatak, D.F., Hashim, H.A., Maulood, M.F., Kabah, K.K., and Abdulamir, A.S. (2020). The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq. medRxiv.","key":"ref_50","DOI":"10.1101\/2020.06.24.20121905"},{"unstructured":"Gharbharan, A., Jordans, C.C., GeurtsvanKessel, C., den Hollander, J.G., Karim, F., Mollema, F.P., Stalenhoef, J.E., Dofferhoff, A., Ludwig, I., and Koster, A. (2020). Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv.","key":"ref_51"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2020.261784","article-title":"Mortality reduction in 46 patients with severe COVID-19 treated with hyperimmune plasma. A proof-of-concept, single-arm, multicenter trial","volume":"105","author":"Perotti","year":"2020","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/jmv.26537","article-title":"Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report","volume":"93","author":"Omrani","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_54","first-page":"759","article-title":"Use of convalescent plasma in hospitalized patients with COVID-19: Case series","volume":"136","author":"Hegerova","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019","volume":"222","author":"Zeng","year":"2020","journal-title":"J. Infect. Dis."},{"doi-asserted-by":"crossref","unstructured":"Donato, M., Park, S., Baker, M., Korngold, R., Morawski, A., Geng, X., Tan, M.T., Rowley, S., Chow, K., and Brown, E. (2020). Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma: A prospective study. medRxiv.","key":"ref_56","DOI":"10.1172\/jci.insight.143196"},{"doi-asserted-by":"crossref","unstructured":"Salazar, M.R., Gonzalez, S.E., Regairaz, L., Ferrando, N.S., Gonzalez, V., Carrera, P.M., Mu\u00f1oz, L., Pesci, S.A., Vidal, J.M., and Kreplak, N. (2020). Effect of convalescent plasma on mortality in patients with COVID-19 pneumonia. medRxiv.","key":"ref_57","DOI":"10.1101\/2020.10.08.20202606"},{"doi-asserted-by":"crossref","unstructured":"Salazar, E., Christensen, P.A., Graviss, E.A., Ngyuen, D.T., Castillo, B., Chen, J., Lopez, B.V., Eager, T., Yi, X., and Zhao, P. (2020). Early transfusion of a large cohort of COVID-19 patients with high titer anti-SARS-CoV-2 spike protein IgG convalescent plasma confirms a signal of significantly decreased mortality. medRxiv.","key":"ref_58","DOI":"10.1101\/2020.10.02.20206029"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: A propensity score\u2013matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.2020007079","article-title":"Improved clinical symptoms and mortality on severe\/critical COVID-19 patients utilizing convalescent plasma transfusion","volume":"136","author":"Xia","year":"2020","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"102875","DOI":"10.1016\/j.transci.2020.102875","article-title":"Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study","volume":"59","author":"Abolghasemi","year":"2020","journal-title":"Transfus. Apher. Sci."},{"doi-asserted-by":"crossref","unstructured":"Rogers, R., Shehadeh, F., Mylona, E., Rich, J., Neill, M., Touzard-Romo, F., Geffert, S., Larkin, J., Bailey, J.A., and Lu, S. (2020). Convalescent plasma for patients with severe COVID-19: A matched cohort study. medRxiv.","key":"ref_62","DOI":"10.1101\/2020.08.18.20177402"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102955","DOI":"10.1016\/j.transci.2020.102955","article-title":"Convalescent plasma therapy in patients with COVID-19","volume":"60","author":"Altuntas","year":"2020","journal-title":"Transfus. Apher. Sci."},{"doi-asserted-by":"crossref","unstructured":"Joyner, M.J., Senefeld, J.W., Klassen, S.A., Mills, J.R., Johnson, P.W., Theel, E.S., Wiggins, C.C., Bruno, K.A., Klompas, A.M., and Lesser, E.R. (2020). Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience. medRxiv.","key":"ref_64","DOI":"10.1101\/2020.08.12.20169359"},{"doi-asserted-by":"crossref","unstructured":"Chen, S., Lu, C., Li, P., Wang, L., Wang, H., Yang, Q., Chen, L., Li, J., Ma, H., and Sang, Q. (2020). Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients. medRxiv.","key":"ref_65","DOI":"10.1101\/2020.08.02.20166710"},{"doi-asserted-by":"crossref","unstructured":"Martinez-Resendez, M.F., Castilleja-Leal, F., Torres-Quintanilla, A., Rojas-Martinez, A., Garcia-Rivas, G., Ortiz-Lopez, R., Trevino, V., Lara-Medrano, R., Villanueva-Lozano, H., and Ramirez-Elizondo, T. (2020). Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. medRxiv.","key":"ref_66","DOI":"10.1101\/2020.07.14.20144469"},{"doi-asserted-by":"crossref","unstructured":"Jin, C., Gu, J., Yuan, Y., Long, Q., Zhang, Q., Zhou, H., Wu, W., and Zhang, W. (2020). Treatment of 6 COVID-19 patients with convalescent plasma. medRxiv.","key":"ref_67","DOI":"10.1101\/2020.05.21.20109512"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.jaip.2020.08.059","article-title":"Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma","volume":"8","author":"Jin","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection","volume":"158","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","article-title":"Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea","volume":"35","author":"Ahn","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1556\/650.2020.31901","article-title":"Successful administration of convalescent plasma in critically ill COVID-19 patients in Hungary: The first two cases","volume":"161","author":"Bobek","year":"2020","journal-title":"Orv. Hetil."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.3346\/jkms.2020.35.e239","article-title":"Convalescent plasma therapy in coronavirus disease 2019: A case report and suggestions to overcome obstacles","volume":"35","author":"Im","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13287-020-01802-8","article-title":"A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: A clinical case report","volume":"11","author":"Peng","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12985-020-01354-6","article-title":"Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: A case report","volume":"17","author":"Xu","year":"2020","journal-title":"Virol. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1016\/j.crwh.2020.e00221","article-title":"The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report","volume":"27","author":"Anderson","year":"2020","journal-title":"Case Rep. Women\u2019s Health"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s42399-020-00315-y","article-title":"Clinical features of COVID-19 in a young man with massive cerebral hemorrhage\u2014Case report","volume":"2","author":"Bao","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"102821","DOI":"10.1016\/j.transci.2020.102821","article-title":"Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis","volume":"59","author":"Karakulak","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102820","DOI":"10.1016\/j.transci.2020.102820","article-title":"Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma","volume":"59","author":"Kong","year":"2020","journal-title":"Transfus. Apher. Sci."},{"key":"ref_79","first-page":"2290","article-title":"Convalescent plasma therapy for B-cell\u2013depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s41231-020-00068-9","article-title":"Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest","volume":"5","author":"Hartman","year":"2020","journal-title":"Transl. Med. Commun."},{"key":"ref_81","first-page":"312","article-title":"Critical Illness Due to Covid-19: A Description of the Surge in a Single Center in Sioux Falls","volume":"73","author":"Jamous","year":"2020","journal-title":"South Dak. Med."},{"key":"ref_82","first-page":"159","article-title":"Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: A pilot study","volume":"72","year":"2020","journal-title":"Rev. Investig. Clin."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1002\/cam4.3457","article-title":"Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients","volume":"9","author":"Tremblay","year":"2020","journal-title":"Cancer Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/jmv.25882","article-title":"Treatment with convalescent plasma for COVID-19 patients in Wuhan, China","volume":"92","author":"Ye","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1093\/labmed\/lmaa045","article-title":"Laboratory Assay Evaluation Demystified: A Review of Key Factors Influencing Interpretation of Test Results Using Different Assays for SARS-CoV-2 Infection Diagnosis","volume":"51","author":"Pham","year":"2020","journal-title":"Lab. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"ftaa069","DOI":"10.1093\/femspd\/ftaa069","article-title":"How can we interpret SARS-CoV-2 antibody test results?","volume":"79","author":"Krogfelt","year":"2021","journal-title":"Pathog. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"104569","DOI":"10.1016\/j.jcv.2020.104569","article-title":"Comparison of different serological assays for SARS-CoV-2 in real life","volume":"130","author":"Brochot","year":"2020","journal-title":"J. Clin. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.23559","article-title":"Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008\u20132011","volume":"88","author":"Menis","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tmrv.2020.04.002","article-title":"COVID-19 convalescent plasma: Now is the time for better science","volume":"34","author":"Dzik","year":"2020","journal-title":"Transfus. Med. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","article-title":"Antibody-dependent enhancement of Ebola virus infection","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1751-2824.2009.01269.x","article-title":"Donor complications and donor care","volume":"4","author":"Nakajima","year":"2009","journal-title":"ISBT Sci. Ser."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): A double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: A multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1542\/peds.100.6.937","article-title":"Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children","volume":"100","author":"Rodriguez","year":"1997","journal-title":"Pediatrics"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:57:48Z","timestamp":1760162268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/5\/849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":94,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["v13050849"],"URL":"https:\/\/doi.org\/10.3390\/v13050849","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2021,5,7]]}}}